PL2056807T3 - Leczenie chorób zakaźnych - Google Patents

Leczenie chorób zakaźnych

Info

Publication number
PL2056807T3
PL2056807T3 PL07837041T PL07837041T PL2056807T3 PL 2056807 T3 PL2056807 T3 PL 2056807T3 PL 07837041 T PL07837041 T PL 07837041T PL 07837041 T PL07837041 T PL 07837041T PL 2056807 T3 PL2056807 T3 PL 2056807T3
Authority
PL
Poland
Prior art keywords
treatment
inflammatory diseases
inflammatory
diseases
Prior art date
Application number
PL07837041T
Other languages
English (en)
Inventor
Betty C Soliven
Original Assignee
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chicago filed Critical Univ Chicago
Publication of PL2056807T3 publication Critical patent/PL2056807T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL07837041T 2006-08-17 2007-08-17 Leczenie chorób zakaźnych PL2056807T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83822206P 2006-08-17 2006-08-17
EP07837041A EP2056807B1 (en) 2006-08-17 2007-08-17 Treatment of inflammatory diseases
PCT/US2007/018331 WO2008021532A2 (en) 2006-08-17 2007-08-17 Treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
PL2056807T3 true PL2056807T3 (pl) 2013-02-28

Family

ID=38941849

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07837041T PL2056807T3 (pl) 2006-08-17 2007-08-17 Leczenie chorób zakaźnych

Country Status (16)

Country Link
US (3) US8258150B2 (pl)
EP (2) EP2056807B1 (pl)
JP (3) JP5216769B2 (pl)
CN (2) CN102526736B (pl)
AU (1) AU2007284337B2 (pl)
BR (1) BRPI0715950A2 (pl)
CA (1) CA2660880C (pl)
DK (1) DK2056807T3 (pl)
ES (1) ES2393631T3 (pl)
HR (1) HRP20121034T1 (pl)
MX (1) MX2009001788A (pl)
PL (1) PL2056807T3 (pl)
PT (1) PT2056807E (pl)
RU (1) RU2440110C2 (pl)
SI (1) SI2056807T1 (pl)
WO (1) WO2008021532A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2046315B1 (en) 2006-06-02 2013-04-10 The Ohio State University Research Foundation Therapeutic agents for the treatment of mantle cell lymphoma
ES2393631T3 (es) * 2006-08-17 2012-12-26 University Of Chicago Tratamiento de enfermedades inflamatorias
MX2011000881A (es) 2008-07-23 2011-03-02 Novartis Ag Moduladores de los receptores de esfingosina-1-fosfato y su uso para tratar inflamacion muscular.
EP2326325B1 (en) * 2008-08-18 2014-11-12 Novartis AG Azetidine derivative for the treatment of peripheral neuropathies
CN102119028A (zh) * 2008-08-18 2011-07-06 诺瓦提斯公司 用于治疗脱髓鞘性周围神经病的氨基醇衍生物
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
US9181182B2 (en) 2008-10-17 2015-11-10 Akaal Pharma Pty Ltd S1P receptors modulators
CA2740484C (en) 2008-10-17 2021-09-21 Akaal Pharma Pty Ltd S1p receptors modulators and their use thereof
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
EP2419414A4 (en) 2009-04-13 2013-12-04 Univ Ohio State Res Found MEANS FOR ACTIVATING PROTEIN PHOSPHATASE 2A
CA2759011A1 (en) 2009-04-17 2010-10-21 The Ohio State University Research Foundation Antiadhesion agents
PL2467372T3 (pl) 2009-08-10 2017-04-28 Teva Pharmaceutical Industries Ltd. Leczenie zaburzeń związanych z BDNF z zastosowaniem lakwinimodu
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
US8889661B2 (en) * 2010-03-03 2014-11-18 Teva Pharmaceutical Industries, Ltd. Treatment of lupus nephritis using laquinimod
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
WO2012074960A2 (en) * 2010-11-29 2012-06-07 The Ohio State University Research Foundation Fty720-derived anticancer agents
US8889627B2 (en) * 2011-10-12 2014-11-18 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
US9161935B2 (en) 2012-02-03 2015-10-20 Teva Pharmaceutical Industries, Ltd. Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
EP2708898A1 (de) 2012-09-14 2014-03-19 Sterna Biologicals GmbH & Co. Kg Verfahren zur Diagnose eines molekularen Phänotyps eines an einer mit chronischen Entzündungen einhergehenden Erkrankung leidenden Patienten
CN104955522A (zh) 2012-11-07 2015-09-30 梯瓦制药工业有限公司 拉喹莫德胺盐
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
CN103992985A (zh) * 2014-05-09 2014-08-20 上海大学 神经鞘氨醇在中枢神经系统中的作用
CN112237575A (zh) * 2020-11-09 2021-01-19 杭州端丽生物技术有限公司 芬戈莫德在防治鞘脂紊乱引起的神经退行性疾病中的医药用途
CN112924432A (zh) * 2021-04-08 2021-06-08 济宁市第一人民医院 一种血液真菌感染检测试剂盒及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
EP1377554A1 (en) * 1999-06-16 2004-01-07 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
KR101095807B1 (ko) 2002-09-24 2011-12-21 노파르티스 아게 탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트
JP4861177B2 (ja) * 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
ES2393631T3 (es) * 2006-08-17 2012-12-26 University Of Chicago Tratamiento de enfermedades inflamatorias

Also Published As

Publication number Publication date
CN101553216B (zh) 2012-03-21
US20100310547A1 (en) 2010-12-09
US9101576B2 (en) 2015-08-11
JP2015221824A (ja) 2015-12-10
CN102526736B (zh) 2016-01-20
DK2056807T3 (da) 2012-10-22
MX2009001788A (es) 2009-09-23
WO2008021532A2 (en) 2008-02-21
PT2056807E (pt) 2012-12-21
CN101553216A (zh) 2009-10-07
WO2008021532A3 (en) 2008-05-29
EP2056807B1 (en) 2012-09-26
US20130017190A1 (en) 2013-01-17
JP2013144694A (ja) 2013-07-25
CN102526736A (zh) 2012-07-04
HK1131047A1 (en) 2010-01-15
SI2056807T1 (sl) 2012-12-31
EP2056807A2 (en) 2009-05-13
BRPI0715950A2 (pt) 2013-07-30
RU2440110C2 (ru) 2012-01-20
AU2007284337B2 (en) 2012-07-19
CA2660880C (en) 2015-10-13
CA2660880A1 (en) 2008-02-21
JP5216769B2 (ja) 2013-06-19
EP2392320A1 (en) 2011-12-07
JP2010500995A (ja) 2010-01-14
AU2007284337A1 (en) 2008-02-21
ES2393631T3 (es) 2012-12-26
US9370497B2 (en) 2016-06-21
RU2009109418A (ru) 2010-09-27
US20150335666A1 (en) 2015-11-26
US8258150B2 (en) 2012-09-04
HRP20121034T1 (hr) 2013-01-31

Similar Documents

Publication Publication Date Title
PL2056807T3 (pl) Leczenie chorób zakaźnych
ZA200707591B (en) Dihyrothienopyrimidines for the treatment of inflammatory diseases
IL200368A0 (en) Treatment of diseases characterized by inflammation
ZA200710598B (en) Treatment of inflammatory conditions
PL2044111T3 (pl) Celowanie czynnika H dopełniacza do leczenia chorób
EP2004204A4 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
PL2056863T3 (pl) Leczenie chorób oczu
ZA200905364B (en) Treatment of diseases characterized by inflammation
ZA200806808B (en) Treatment of stressed patients
GB0700972D0 (en) Treatment of inflammatory disease
IL200091A (en) Kittensan to treat infectious diseases of the nail
PL2380585T3 (pl) Sposoby leczenia chorób autoimmunologicznych
GB0720976D0 (en) Treatment of inflammatory disease
EP1981343A4 (en) TREATMENT OF INFLAMMATORY DISEASES WITH TRIAZOL COMPOUNDS
GB0610183D0 (en) Treatment of neurodegenerative diseases
GB0723100D0 (en) Treatment of HFnEF
GB0526394D0 (en) Treatment of inflammatory diseases
GB0622136D0 (en) Treatment of gastrointestinal diseases
GB0623740D0 (en) Treatment of disease
ZA200904660B (en) Treatment of IL-1-Beta related diseases
GB0622137D0 (en) Treatment of gastrointestinal diseases
GB0611417D0 (en) Treatment of cndaria intoxication
GB0819446D0 (en) Treatment of inflammatory disorders
IL194261A0 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
GB0411302D0 (en) Treatment of inflammatory diseases